REPLReplimune Group, Inc.

• 2026-08-19 · Hill Emily Luisa (Chief Financial Officer) · SELL
• 2026-08-12 · Hill Emily Luisa (Chief Financial Officer) · SELL
• 2026-08-12 · Xynos Konstantinos (Chief Medical Officer) · SELL
• 2026-08-12 · Patel Sushil (Chief Executive Officer) · SELL
• 2026-08-12 · Schwendenman Andrew (Chief Accounting Officer) · SELL

• Replimune launches melanoma therapy in US market
• Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
• SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026
• REPL: Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1
• REPL: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc